(-)-MDL 100907
Modify Date: 2024-01-14 11:27:11
(-)-MDL 100907 structure
|
Common Name | (-)-MDL 100907 | ||
|---|---|---|---|---|
| CAS Number | 175673-57-1 | Molecular Weight | 373.46 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H28FNO3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of (-)-MDL 100907(S)-Volinanserin is an isform of Volinanserin (HY-14940). Volinanserin is a potent and selective antagonist of 5-HT2 receptor, with a Ki of 0.36 nM, and shows 300-fold selectivity for 5-HT2 receptor over 5-HT1c, alpha-1 and DA D2 receptors. Volinanserin has antipsychotic activity. |
| Name | (S)-(2,3-Dimethoxyphenyl){1-[2-(4-fluorophenyl)ethyl]-4-piperidin yl}methanol |
|---|---|
| Synonym | More Synonyms |
| Description | (S)-Volinanserin is an isform of Volinanserin (HY-14940). Volinanserin is a potent and selective antagonist of 5-HT2 receptor, with a Ki of 0.36 nM, and shows 300-fold selectivity for 5-HT2 receptor over 5-HT1c, alpha-1 and DA D2 receptors. Volinanserin has antipsychotic activity. |
|---|---|
| Related Catalog | |
| Target |
Ki: 0.36 nM (5-HT2 receptor)[1] |
| References |
| Molecular Formula | C22H28FNO3 |
|---|---|
| Molecular Weight | 373.46 |
| Exact Mass | 373.20500 |
| PSA | 41.93000 |
| LogP | 3.76890 |
| Storage condition | -20°C |
|
~98%
(-)-MDL 100907 CAS#:175673-57-1 |
| Literature: Ullrich, Thomas; Rice, Kenner C. Bioorganic and Medicinal Chemistry, 2000 , vol. 8, # 10 p. 2427 - 2432 |
|
~%
(-)-MDL 100907 CAS#:175673-57-1 |
| Literature: Morris, David J.; Hayes, Aidan M.; Wills, Martin Journal of Organic Chemistry, 2006 , vol. 71, # 18 p. 7035 - 7044 |
|
~%
(-)-MDL 100907 CAS#:175673-57-1 |
| Literature: Morris, David J.; Hayes, Aidan M.; Wills, Martin Journal of Organic Chemistry, 2006 , vol. 71, # 18 p. 7035 - 7044 |
|
~%
(-)-MDL 100907 CAS#:175673-57-1 |
| Literature: Morris, David J.; Hayes, Aidan M.; Wills, Martin Journal of Organic Chemistry, 2006 , vol. 71, # 18 p. 7035 - 7044 |
|
~%
(-)-MDL 100907 CAS#:175673-57-1 |
| Literature: Morris, David J.; Hayes, Aidan M.; Wills, Martin Journal of Organic Chemistry, 2006 , vol. 71, # 18 p. 7035 - 7044 |
|
~%
(-)-MDL 100907 CAS#:175673-57-1 |
| Literature: Ullrich, Thomas; Rice, Kenner C. Bioorganic and Medicinal Chemistry, 2000 , vol. 8, # 10 p. 2427 - 2432 |
|
~%
(-)-MDL 100907 CAS#:175673-57-1 |
| Literature: Huang, Yiyun; Mahmood, Khalid; Mathis, Chester A. Journal of Labelled Compounds and Radiopharmaceuticals, 1999 , vol. 42, # 10 p. 949 - 957 |
![1-[2-(4-fluorophenyl)-ethyl]-piperidine-4-carboxylic acid ethyl ester structure](https://www.chemsrc.com/caspic/318/175553-31-8.png)
![1-[2-(4-fluorophenyl)ethyl]-4-piperidinecarboxylic acid N-methoxy N-methyl amide structure](https://www.chemsrc.com/caspic/280/175553-32-9.png)
![(+/-)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINE-METHANOL structure](https://www.chemsrc.com/caspic/101/139290-69-0.png)
| (S)-(2,3-dimethoxyphenyl)-{1-[2-(4-fluorophenyl)-ethyl]-piperidin-4-yl}-methanol |
| (R)-(2,3-dimethoxyphenyl)-{1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl}methanol |
| (S)-(+)-Tricyclamoliodid |
| 1-[(3s)-3-cyclohexyl-3-hydroxy-3-phenylpropyl]-1-methylpyrrolidinium iodide |